María Soledad Sáez1, Juan Ignacio Rojas2,3, María Victoria Lorenzón1, Francisco Sánchez4, Liliana Patrucco4, Jimena Míguez4, Carolina Azcona5, Patricia Sorroche1, Edgardo Cristiano4. 1. Central Laboratory, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 2. Multiple Sclerosis Center of Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. juan.rojas@hospitalitaliano.org.ar. 3. Servicio de Neurología (Neurology Department), Hospital Italiano de Buenos Aires, Gascón 450, 1181, Buenos Aires, Argentina. juan.rojas@hospitalitaliano.org.ar. 4. Multiple Sclerosis Center of Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 5. Neurology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Abstract
BACKGROUND: The objective was to evaluate the precision of kappa and lambda free light chains (KFLC and LFLC) in CSF for the diagnosis of multiple sclerosis (MS) and prognosis of clinically isolated syndrome (CIS). METHODS: CSF and serum samples from CIS, MS and other neurological non-MS disease were collected between 2015 and 2017. FLC concentrations were measured using immunoassay Freelite™. Results were correlated with the patients' diagnoses and ROC curve analysis was used to determine accuracy. In CIS patients, analysis of FLC were compared in CIS converters vs. non-converter during follow-up. RESULTS: In the MS group (n = 41), the optimal cut-off for KFLC determined was 7 mg/L, with a diagnostic sensitivity and specificity of 95% and 97%, respectively. The optimal cut-off for LFLC was 0.7 mg/L, with a diagnostic sensitivity and specificity of 71% and 81%, respectively. 36 CIS patients were included; mean follow-up time was 28 ± 9 months, and 22 (61.1%) patients converted to MS. The median concentration of CSF K and LFLCs at CIS diagnosis was slightly higher in CIS-converters compared to non-converters, but this did not reach statistical significance (KFLC: median 7 ± 5.3 mg/L vs. 5 ± 2.3 mg/L, p = 0.11; LFLC 0.7 ± 0.33 mg/L vs. 0.5 ± 0.23 mg/L p = 0.16). A strong correlation was observed between the concentration of K and L FLCs at diagnosis and the change in PBVC during follow-up (r = 0.72 and r = 0.65, respectively). CONCLUSION: KFLCs have a high sensitivity and specificity for the diagnosis of MS. FLC concentrations at CIS diagnosis were not significantly higher in CIS-converters.
BACKGROUND: The objective was to evaluate the precision of kappa and lambda free light chains (KFLC and LFLC) in CSF for the diagnosis of multiple sclerosis (MS) and prognosis of clinically isolated syndrome (CIS). METHODS:CSF and serum samples from CIS, MS and other neurological non-MS disease were collected between 2015 and 2017. FLC concentrations were measured using immunoassay Freelite™. Results were correlated with the patients' diagnoses and ROC curve analysis was used to determine accuracy. In CIS patients, analysis of FLC were compared in CIS converters vs. non-converter during follow-up. RESULTS: In the MS group (n = 41), the optimal cut-off for KFLC determined was 7 mg/L, with a diagnostic sensitivity and specificity of 95% and 97%, respectively. The optimal cut-off for LFLC was 0.7 mg/L, with a diagnostic sensitivity and specificity of 71% and 81%, respectively. 36 CIS patients were included; mean follow-up time was 28 ± 9 months, and 22 (61.1%) patients converted to MS. The median concentration of CSF K and LFLCs at CIS diagnosis was slightly higher in CIS-converters compared to non-converters, but this did not reach statistical significance (KFLC: median 7 ± 5.3 mg/L vs. 5 ± 2.3 mg/L, p = 0.11; LFLC 0.7 ± 0.33 mg/L vs. 0.5 ± 0.23 mg/L p = 0.16). A strong correlation was observed between the concentration of K and L FLCs at diagnosis and the change in PBVC during follow-up (r = 0.72 and r = 0.65, respectively). CONCLUSION: KFLCs have a high sensitivity and specificity for the diagnosis of MS. FLC concentrations at CIS diagnosis were not significantly higher in CIS-converters.
Authors: M Puthenparampil; S Altinier; E Stropparo; S Zywicki; D Poggiali; C Cazzola; E Toffanin; S Ruggero; F Grassivaro; M Zaninotto; M Plebani; P Gallo Journal: Mult Scler Relat Disord Date: 2018-08-10 Impact factor: 4.339
Authors: Margarete M Voortman; Tatjana Stojakovic; Lukas Pirpamer; Margit Jehna; Christian Langkammer; Hubert Scharnagl; Markus Reindl; Stefan Ropele; Thomas Seifert-Held; Juan-Jose Archelos; Siegrid Fuchs; Christian Enzinger; Franz Fazekas; Michael Khalil Journal: Mult Scler Date: 2016-11-29 Impact factor: 6.312
Authors: Nicola De Stefano; Maria Laura Stromillo; Francesca Rossi; Marco Battaglini; Antonio Giorgio; Emilio Portaccio; Bahia Hakiki; Gianmichele Malentacchi; Claudio Gasperini; Mario Santangelo; Maria Letizia Bartolozzi; Maria Pia Sormani; Antonio Federico; Maria Pia Amato Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman Journal: Neurology Date: 2014-05-28 Impact factor: 9.910
Authors: Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Hayrettin Tumani; Marie Süße; Thomas Skripuletz Journal: Cells Date: 2021-11-06 Impact factor: 6.600